Impact of Metabolic Bariatric Surgery on Antidepressant Drug Absorption
Overview
This study evaluated pharmacokinetic changes in antidepressant drug absorption following Roux-en-Y gastric bypass (RYGB) in patients with obesity and medication-dependent depression. Fourteen patients were analyzed longitudinally, revealing significant alterations in drug clearance and concentration-to-dose ratios post-surgery, particularly for fluoxetine.
Background
Obesity is a chronic disease affecting billions worldwide, often accompanied by mood disorders such as depression. Metabolic bariatric surgery (MBS), especially RYGB, is the most effective long-term weight-loss intervention but may alter drug metabolism due to its hypoabsorptive effects. Given the high prevalence of antidepressant use in this population and concerns about altered pharmacokinetics post-surgery, understanding these changes is critical for optimizing psychiatric treatment.
Data Highlights
Measurement
Mean Age (years)
Mean BMI (kg/m2)
Total Weight Loss (%)
Baseline (M1)
48.92 (SD 2.32)
37.32 (SD 1.1)
--
6-15 months post-surgery (M3)
--
--
28.41 (SD 2.69)
Key Findings
Fourteen patients (10 females) with a mean age of 48.92 years and baseline BMI of 37.32 kg/m2 were studied longitudinally before and after RYGB.
Significant weight loss was observed post-surgery, with a mean total weight loss of 28.41% at 6-15 months.
Pharmacokinetic analysis showed changes in apparent oral clearance (CL/F) and concentration-to-dose ratio (CDR) of antidepressants post-RYGB.
Fluoxetine was the most commonly used antidepressant, and its pharmacokinetics were specifically analyzed due to its weight loss benefits and safety profile.
A linear mixed-effects model demonstrated a significant relationship between BMI reduction and changes in fluoxetine CDR over time.
Clinical Implications
Clinicians should be aware that RYGB can significantly alter the pharmacokinetics of antidepressant medications, potentially affecting drug efficacy and safety. Monitoring plasma drug levels and adjusting doses post-surgery may be necessary, especially for fluoxetine, to ensure optimal therapeutic outcomes in patients undergoing bariatric surgery.
Conclusion
RYGB induces significant pharmacokinetic changes in antidepressant drug absorption, underscoring the need for individualized therapeutic drug monitoring in patients with obesity and depression undergoing bariatric surgery.
References
World Health Organization 2022 -- Global Obesity and Overweight Statistics
Hiemke et al. -- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology
by Lucas Sabatella, Azucena Aldaz Pastor, Manuel Fortún Landecho Acha, Rafael Moncada Durruti, Daniel Aliseda Jover, Nuria Blanco Asensio, Victor Valentí Azcárate
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.
